| 可速普特的药理和临床应用 |
| |
| 引用本文： | 车宁,谭玲,傅得兴,张尧贞. 可速普特的药理和临床应用[J]. 中国新药杂志, 2005, 14(5): 631-634 |
| |
| 作者姓名： | 车宁 谭玲 傅得兴 张尧贞 |
| |
| 作者单位： | 1. 卫生部北京医院药剂科,北京,100730
2. 卫生部北京医院眼科,北京,100730 |
| |
| 摘 要： | 可速普特(Cosopt)是0.5%噻吗洛尔(timolol)和2%多佐胺(dorzolamide)组成的复方制剂,供局部眼用.噻吗洛尔属于非选择性β-受体阻滞剂,通过抑制眼睫状突的β2受体,减少房水生成,降低眼压.而多佐胺属于碳酸酐酶抑制剂(CAI),强效抑制存在于睫状突和视网膜中的碳酸酐酶(CA)-Ⅱ,减少房水生成,有效降低眼内压(IOP).二者合用有相加作用.可速普特主要用于高眼压症,原发性开角型青光眼.全身性不良反应少.
|
| 关 键 词： | 可速普特 青光眼 噻吗洛尔 多佐胺 药理 临床应用 |
| 文章编号： | 1003-3734(2005)05-0631-04 |
Pharmacology and clinical application of cosopt |
| |
| CHE Ning,TANG Ling,FU De-xing,ZHANG Yao-zhen. Pharmacology and clinical application of cosopt[J]. Chinese Journal of New Drugs, 2005, 14(5): 631-634 |
| |
| Authors: | CHE Ning TANG Ling FU De-xing ZHANG Yao-zhen |
| |
| Abstract: | Cosopt is a sterile ophthalmic solution containing the combination of a topical carbonic anhydrase inhibitor (2% dorzolamide hydrochloride) and a topical non-selective beta-adrenergic receptor blocking agent (5% timolol maleate). Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion in the ciliary process of the eye. Cosopt is indicated for the primary open-angle glaucoma (POAG) and ocular hypertension (OH). Cosopt is generally well tolerated and does not produce the systemic adverse effects associated. |
| |
| Keywords: | cosopt glaucoma timolol dorzolamide pharmacology clinical application |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
